Latest news with #Novogene
Korea Herald
18 hours ago
- Business
- Korea Herald
Novogene Establishes New Subsidiary in Korea to Accelerate Multi-Omics Research
SEOUL, South Korea, June 23, 2025 /PRNewswire/ -- Novogene, a global leader in next-generation sequencing (NGS) and multi-omics solutions, today announced the establishment of Novogene Korea Limited, a wholly owned subsidiary headquartered in Seoul. This strategic expansion deepens Novogene's long-standing engagement with Korea's biomedical and biotech sectors, reinforcing its commitment to delivering rapid, high-quality, and cost-effective multi-omics services tailored to local research needs. The new entity provides localized customer support, shorter project timelines, and stronger collaboration with Korea's vibrant scientific community — spanning cancer genomics, microbiome studies, precision medicine, and agricultural genomics. Novogene empowers researchers to accelerate discoveries across genomics, transcriptomics, proteomics, metabolomics, and beyond. "South Korea is a global innovation hub, and by establishing a dedicated team in Seoul, we are investing in the future of multi-omics discovery," said Justin Lee, Vice President, Novogene Asia Pacific, Middle East & Africa (AMEA). "With the launch of Novogene Korea, we are even better positioned to support our customers with rapid, cost-effective, and reliable services that are already trusted by more than 7,300 organizations worldwide. We sincerely thank the Korean scientific community for their continued trust and collaboration in advancing the frontiers of science." Backed by robust government R&D support, world-class academic institutions, and a dynamic biotech ecosystem, South Korea is uniquely positioned to lead the next wave of genomic innovation. Novogene Korea will partner closely with universities, start-ups, and research hospitals to help unlock transformative insights in health, agriculture, and beyond. About Novogene Novogene is a global leader in applying cutting-edge molecular biology technologies and high-performance computing to advance life science and human health research. With one of the world's largest sequencing capacities, Novogene delivers industry-leading multi-omics solutions to academic institutions, clinical researchers, and pharmaceutical companies worldwide. Driven by scientific excellence, trusted service, and uncompromising data quality, Novogene empowers researchers to accelerate discoveries across genomics, transcriptomics, proteomics, metabolomics, and beyond. As a pioneer in multi-omics, Novogene is committed to being your trusted partner in navigating the future of life science innovation.
Korea Herald
05-06-2025
- Business
- Korea Herald
Novogene Certified for Olink® Services Across Multiple Labs; Expands Proteomics Portfolio with Olink® Reveal
SINGAPORE, June 5, 2025 /PRNewswire/ -- Novogene, a global leader in multi-omics solutions, is proud to announce its designation as an Olink ® Certified Service Provider (CSP) across multiple laboratories worldwide. This milestone positions Novogene among the first globally to offer high-throughput, high-quality protein biomarker discovery services using Olink's leading proteomics platforms. This multi-site certification validates Novogene's capabilities to execute Olink ® workflows with exceptional precision, consistency, and scalability across global labs—enabling advanced translational research and precision medicine for pharmaceutical, biotech, and academic partners. Novogene has broadened its suite of high-plex proteomics, with the addition of Olink ® Reveal. Olink ® Reveal enables the quantification of ~1,000 curated human proteins, including 537 inflammation markers, spanning 96% of immune response pathways and 64% of all Reactome pathways. The assay features validated, biologically relevant content enriched with cis-pQTLs—ideal for proteogenomic applications—allowing researchers to both broadly screen the proteome and deeply investigate inflammation biology. "Being certified as an Olink ® CSP across multiple Novogene labs underscores our commitment to delivering high-quality, globally harmonized data. With Olink ® Reveal offering deep insights into inflammatory biology, we empower researchers to accelerate biomarker discovery, translational research, and precision medicine. This recognition further enhances Novogene's leadership in comprehensive multi-omics solutions." said Justin Lee, Novogene VP of Global Marketing. "We are extremely excited to see Olink ® proteomics solutions being adopted by Novogene, a global provider of multi-omics solutions," said Andrea Ballagi, Olink VP of Sales and Marketing. "As part of a worldwide network of Olink ® Certified Service Providers, Novogene is well-positioned to enable scientists around the world to advance biomarker research and contribute to a healthier, cleaner and safer world". As part of the Olink ® global CSP network, Novogene is committed to deliver reproducible, high-quality data to empower the exploration of disease mechanisms, therapeutic targets, and novel biomarkers. About Novogene Novogene is a global leader in applying cutting-edge molecular biology technologies and high-performance computing to advance life science and human health research. With one of the world's largest sequencing capacities, Novogene delivers industry-leading multi-omics solutions to academic institutions, clinical researchers, and pharmaceutical companies worldwide. Driven by scientific excellence, trusted service, and uncompromising data quality, Novogene empowers researchers to accelerate discoveries across genomics, transcriptomics, proteomics, metabolomics, and beyond. As a pioneer in multi-omics, Novogene is committed to being your trusted partner in navigating the future of life science innovation.
Yahoo
05-06-2025
- Business
- Yahoo
Novogene Certified for Olink® Services Across Multiple Labs; Expands Proteomics Portfolio with Olink® Reveal
SINGAPORE, June 5, 2025 /PRNewswire/ -- Novogene, a global leader in multi-omics solutions, is proud to announce its designation as an Olink® Certified Service Provider (CSP) across multiple laboratories worldwide. This milestone positions Novogene among the first globally to offer high-throughput, high-quality protein biomarker discovery services using Olink's leading proteomics platforms. This multi-site certification validates Novogene's capabilities to execute Olink® workflows with exceptional precision, consistency, and scalability across global labs—enabling advanced translational research and precision medicine for pharmaceutical, biotech, and academic partners. Novogene has broadened its suite of high-plex proteomics, with the addition of Olink® Reveal. Olink® Reveal enables the quantification of ~1,000 curated human proteins, including 537 inflammation markers, spanning 96% of immune response pathways and 64% of all Reactome pathways. The assay features validated, biologically relevant content enriched with cis-pQTLs—ideal for proteogenomic applications—allowing researchers to both broadly screen the proteome and deeply investigate inflammation biology. "Being certified as an Olink® CSP across multiple Novogene labs underscores our commitment to delivering high-quality, globally harmonized data. With Olink® Reveal offering deep insights into inflammatory biology, we empower researchers to accelerate biomarker discovery, translational research, and precision medicine. This recognition further enhances Novogene's leadership in comprehensive multi-omics solutions." said Justin Lee, Novogene VP of Global Marketing. "We are extremely excited to see Olink® proteomics solutions being adopted by Novogene, a global provider of multi-omics solutions," said Andrea Ballagi, Olink VP of Sales and Marketing. "As part of a worldwide network of Olink® Certified Service Providers, Novogene is well-positioned to enable scientists around the world to advance biomarker research and contribute to a healthier, cleaner and safer world". As part of the Olink® global CSP network, Novogene is committed to deliver reproducible, high-quality data to empower the exploration of disease mechanisms, therapeutic targets, and novel biomarkers. About NovogeneNovogene is a global leader in applying cutting-edge molecular biology technologies and high-performance computing to advance life science and human health research. With one of the world's largest sequencing capacities, Novogene delivers industry-leading multi-omics solutions to academic institutions, clinical researchers, and pharmaceutical companies worldwide. Driven by scientific excellence, trusted service, and uncompromising data quality, Novogene empowers researchers to accelerate discoveries across genomics, transcriptomics, proteomics, metabolomics, and beyond. As a pioneer in multi-omics, Novogene is committed to being your trusted partner in navigating the future of life science innovation. CONTACT: Novogene AMEA (APAC, Middle-East & Africa)marketing_amea@ View original content: SOURCE Novogene
